Immuneering at ENA 2026

Nov 18–20, 2026 Barcelona, Spain ~1.5k attendees Website

Immuneering brings 2 presentations to ENA 2026 in Barcelona. Its posters centre on combination strategies for atebimetinib (IMM-1-104), a deep cyclic MEK inhibitor. They cover pairing it with chemotherapy in anaplastic thyroid cancer and using patient-aligned 3D tumor models to find biomarker-enriched combinations in pancreatic ductal adenocarcinoma.

Organization	ENA 2026 Attendance
Immuneering Cambridge, Massachusetts
immuneering.com Biotech Clinical-stage oncology company developing atebimetinib, a deep cyclic MEK inhibitor for MAPK-driven cancers.	Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Translational Studies Atebimetinib, a deep cyclic inhibitor of MEK, combined with chemotherapy: preclinical rationale for treatment of anaplastic thyroid cancer (ATC) Biomarkers Talk Thu Nov 19 2:20–2:25pm Part of Posters in the Spotlight, session 1 Patient-aligned 3D tumor models identify biomarker-enriched atebimetinib (IMM-1-104) combination strategies in pancreatic ductal adenocarcinoma Preclinical models · Targeted agents

Organization

ENA 2026 Attendance

Immuneering

Cambridge, Massachusetts

immuneering.com

Biotech

Clinical-stage oncology company developing atebimetinib, a deep cyclic MEK inhibitor for MAPK-driven cancers.

Poster

Wed Nov 18
12–1:30pm
3:50–4:15pm
5:45–7pm

Part of Poster session: Translational Studies

Atebimetinib, a deep cyclic inhibitor of MEK, combined with chemotherapy: preclinical rationale for treatment of anaplastic thyroid cancer (ATC)

Biomarkers